Ultime notizie per RenovoRx (NASDAQ:RNXT) Azioni

RenovoRx

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

RenovoRx Inc

Fourth Quarter 2024 Outlook
For the fourth quarter 2024, the Company expects:
<ul>
<li>Revenue growth on a constant currency basis in the range of 10.3%-13.3%. This represents revenue in the range of $375-$385 million, assuming FX rates remain relatively stable with the end of Q3.&nbsp;</li>
<li>Adjusted EBITDA in the range of $9-$14 million, representing an Adjusted EBITDA Margin in the range of 2.4%-3.6%.&nbsp;</li>
</ul>

News

Guidance

WBTN

WEBTOON Entertainment Sees Q4 Revenue Growth On A Constant Currency Basis In The Range Of 10.3%-13.3% ($375M-$385M) Vs $375.92M Est.

Tidewater Sees 2024 Revenue $1.33B-$1.35B vs $1.39B Est.

Innodata (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.13 by 169.23 percent. The company reported quarterly sales of $52.224 million which beat the analyst consensus estimate of $36.113 million by 44.61 percent. This is a 135.57 percent increase over sales of $22.169 million the same period last year.

Earnings

Earnings Beats

INOD

Innodata Q3 2024 Adj. EPS $0.35 Beats $0.13 Estimate, Sales $52.224M Beat $36.113M Estimate

ABNB

Airbnb Sees Q4 2024 Revenue $2.39B-$2.44B Vs $3.717B Est.

Ouster (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.57) by 5.26 percent. This is a 39.33 percent increase over losses of $(0.89) per share from the same period last year. The company reported quarterly sales of $28.07 million which beat the analyst consensus estimate of $28.02 million by 0.20 percent. This is a 26.41 percent increase over sales of $22.21 million the same period last year.

OUST

Ouster Q3 EPS $(0.54) Beats $(0.57) Estimate, Sales $28.07M Beat $28.02M Estimate

AFRM

Affirm Sees FY25 GMV OF More Than $34B

Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.47) by 25.53 percent. This is a 1083.33 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $2.975 million which missed the analyst consensus estimate of $3.020 million by 1.49 percent. This is a 9.82 percent decrease over sales of $3.299 million the same period last year.

Earnings Misses

AXDX

Accelerate Diagnostics Q3 2024 GAAP EPS $(0.59) Misses $(0.47) Estimate, Sales $2.975M Miss $3.020M Estimate

Financial Outlook for Full Year 2024
The following tables summarize Getty Images' updated fiscal year 2024 guidance:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Updated 2024 Guidance</td>
<td>Prior 2024 Guidance</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Revenue</td>
<td>$934 million to $943 million</td>
<td>$924 million to $943 million</td>
</tr>
<tr>
<td>Revenue YoY</td>
<td>1.9% to 2.9%</td>
<td>0.9% to 2.9%</td>
</tr>
<tr>
<td>Revenue YoY, Currency Neutral</td>
<td>1.6% to 2.6%</td>
<td>1.0% to 3.0%</td>
</tr>
<tr>
<td>Adjusted EBITDA</td>
<td>$292 million to $294 million</td>
<td>$290 million to $294 million</td>
</tr>
<tr>
<td>Adjusted EBITDA YoY</td>
<td>(3.1)% to (2.5)%</td>
<td>(3.8)% to (2.5)%</td>
</tr>
<tr>
<td>Adjusted EBITDA YoY, Currency Neutral</td>
<td>(3.4)% to (2.8)%</td>
<td>(3.6)% to (2.3)%</td>
</tr>
</tbody>
</table>
</figure>
 Guidance has been updated to reflect the Company's financial performance year to date and the impact of foreign currency exchange rates on both Revenue and Adjusted EBITDA.

GETY

Getty Images Raises FY24 Revenue From $924M-$943M To $934M-$943M Vs $932.61M Est.

Affirm Sees Q2 Revenue $770M-$810M

CPAY

Corpay Narrows FY24 Total Revenue Outlook From $3.975B - $4.025B To $3.98B - $4.01B (Est $3.989B), Adjusted EPS Forecast From $18.85 - $19.15. To $18.90 - $19.10 (Est $18.96)

Upland Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPLD#NASDAQ">UPLD</a>) narrows FY2024 sales outlook from $269.60 million-281.60 million to $272.60 million-278.60 million.

UPLD

Upland Software Narrows FY2024 Sales Guidance from $269.60M-281.60M to $272.60M-278.60M  VS Est.274.57M

Vinci Partners Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINP#NASDAQ">VINP</a>) reported quarterly earnings of $1.08 per share which beat the analyst consensus estimate of $1.01 by 6.93 percent. The company reported quarterly sales of $112.716 million which beat the analyst consensus estimate of $110.552 million by 1.96 percent. This is a 414.00 percent increase over sales of $21.929 million the same period last year.

VINP

Vinci Partners Inv Q3 2024 Adj. EPS $1.08 Beats $1.01 Estimate, Sales $112.716M Beat $110.552M Estimate

Green Dot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDOT#NYSE">GDOT</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.17 by 23.53 percent. The company reported quarterly sales of $406.019 million which beat the analyst consensus estimate of $392.579 million by 3.42 percent. This is a 16.48 percent increase over sales of $348.571 million the same period last year.

GDOT

Green Dot Q3 2024 Adj. EPS $0.13 Misses $0.17 Estimate, Sales $406.019M Beat $392.579M Estimate

Clearfield (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLFD#NASDAQ">CLFD</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.19) by 68.42 percent. This is a 135.29 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $46.77 million which beat the analyst consensus estimate of $41.95 million by 11.49 percent. This is a 5.86 percent decrease over sales of $49.69 million the same period last year.

CLFD

Clearfield Q4 EPS $(0.06) Beats $(0.19) Estimate, Sales $46.77M Beat $41.95M Estimate

Ouster (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) sees Q4 sales of $29.000 million-31.000 million vs $29.93 million estimate.

Ouster Sees Q4 Sales $29.000M-31.000M vs $29.93M Est

AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) is looking for Q4 Adj EPS of $0.18-0.19 vs $0.01 analyst estimate. sees sales of $9.700 million-9.800 million vs $9.47 million estimate.

AEYE

AudioEye Sees Q4 Adj EPS $0.18-0.19 vs $0.01 Est; Sees Sales $9.700M-9.800M vs $9.47M Est

Business Outlook
Gary Yu further commented, "For the fourth quarter of 2024, we expect revenue to be approximately $337 million, plus or minus 3 percent, representing a 3.7% sequential decrease at the mid-point, slightly better than typical seasonality. GAAP gross margin is expected to be 33.0 percent, plus or minus 1 percent. Non-GAAP operating expenses, which are GAAP operating expenses adjusted for amortization of acquisition-related intangible assets, are expected to be approximately 28.0 percent of revenue, plus or minus 1 percent. We expect net interest income to be approximately $2.5 million. Our income tax rate is expected to be 18.0 percent, plus or minus 3 percent, and shares used to calculate diluted EPS for the fourth quarter are anticipated to be approximately 46.7 million."
Amortization of acquisition-related intangible assets of $3.1 million, after tax, for previous acquisitions is not included in these non-GAAP estimates.

DIOD

Diodes Inc. Sees Q4 Revenue ~$337M +/- 3% Vs $351.74M Est.

AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) raises FY2024 Adj EPS guidance from $0.51-0.53 to $0.54-0.55 vs $(0.13) analyst estimate. Raises FY2024 sales outlook from $35.15 million-35.25 million to $35.20 million-35.30 million vs $34.93 million estimate.

AudioEye Raises FY2024 Adj EPS Guidance from $0.51-0.53 to $0.54-0.55 vs $(0.13) Est; Raises FY2024 Sales Guidance from $35.15M-35.25M to $35.20M-35.30M vs $34.93M Est

Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.56) by 25 percent.

LTRN

Lantern Pharma Q3 2024 GAAP EPS $(0.42) Beats $(0.56) Estimate

Upland Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPLD#NASDAQ">UPLD</a>) sees Q4 sales of $65.900 million-71.900 million vs $67.71 million estimate.

Upland Software Sees Q4 Sales $65.900M-71.900M vs $67.71M Est

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out as we get into all of the hottest news happening on Tuesday morning!



Moving stocks this morning are earnings reports, clinical trial data and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Biophytis (NASDAQ:<a href="https://investorplace.com/stock-quotes/bpts-stock-quote/">BPTS</a>) stock is rocketing close to 50% after <a href="https://www.nasdaq.com/press-release/biophytis-announces-its-2023-financial-results-and-provides-an-update-on-its-business">announcing its 2023 results</a>.</li>



<li>MyMD Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mymd-stock-quote/">MYMD</a>) shares are rising over 26% after revealing a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318224188&amp;type=PDF&amp;symbol=MYMD&amp;cdn=8720a94b32a7a67a8aeafa7ccea08ffe&amp;companyName=MyMD+Pharmaceuticals+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-08">securities purchase agreement</a>.</li>



<li>Acorda Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/acor-stock-quote/">ACOR</a>) stock is soaring more than 26% <a href="https://www.nasdaq.com/press-release/acorda-therapeutics-announces-nasdaq-delisting-notification-2024-04-03">ahead of its delisting</a>.</li>



<li>Addex Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/adxn-stock-quote/">ADXN</a>) shares are surging over 26% without any clear news this morning.</li>



<li>TuanChe (NASDAQ:<a href="https://investorplace.com/stock-quotes/tc-stock-quote/">TC</a>) stock is gaining nearly 17% despite a lack of news today.</li>



<li>Anghami (NASDAQ:<a href="https://investorplace.com/stock-quotes/angh-stock-quote/">ANGH</a>) shares are increasing more than 16% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318224555&amp;type=PDF&amp;symbol=ANGH&amp;cdn=55a7014ffb2fa2fae4e6fc7d8965ee6d&amp;companyName=Anghami+Inc.&amp;formType=SC+13D&amp;formDescription=General+statement+of+acquisition+of+beneficial+ownership&amp;dateFiled=2024-04-08">following an investor update</a>.</li>



<li>MediaCo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mdia-stock-quote/">MDIA</a>) stock is climbing over 14% on Tuesday morning.</li>



<li>Brainstorm Cell (NASDAQ:<a href="https://investorplace.com/stock-quotes/bcli-stock-quote/">BCLI</a>) shares are getting a more than 13% boost with an update on its <a href="https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-announces-agreement-with-fda-on-a-special-protocol">Phase 3 clinical trial</a>.</li>



<li>Destiny Tech100 (NYSE:<a href="https://investorplace.com/stock-quotes/dxyz-stock-quote/">DXYZ</a>) stock is jumping over 13% as it <a href="https://seekingalpha.com/article/4682523-destiny-tech100-inc-dxyz-rose-800-percent-in-just-days-a-closer-look">continues a recent rally</a>.</li>



<li>RenovoRx (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnxt-stock-quote/">RNXT</a>) shares are up more than 12% on <a href="https://www.nasdaq.com/press-release/renovorx-announces-%2411.1-million-at-market-private-placement-2024-04-08">an offer to take it private</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Vincerx Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/vinc-stock-quote/">VINC</a>) stock is crashing over 53% on <a href="https://www.nasdaq.com/press-release/vincerx-pharma-presents-positive-preliminary-phase-1-data-for-vip236-and-updates-on">preliminary Phase 1 clinical trial data</a>.</li>



<li>Focus Universal (NASDAQ:<a href="https://investorplace.com/stock-quotes/fcuv-stock-quote/">FCUV</a>) shares are plummeting more than 30% on Tuesday morning.</li>



<li>UTime (NASDAQ:<a href="https://investorplace.com/stock-quotes/wto-stock-quote/">WTO</a>) stock is diving over 23% after a major rally yesterday.</li>



<li>Vivos Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vvos-stock-quote/">VVOS</a>) shares are tumbling more than 22% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318224743&amp;type=PDF&amp;symbol=VVOS&amp;cdn=01c96e38759646a4b342ce7c55cb1bd1&amp;companyName=Vivos+Therapeutics+Inc.&amp;formType=S-1&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2024-04-09">proposed public offering</a>.</li>



<li>BioSig Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsgm-stock-quote/">BSGM</a>) stock is taking an over 21% beating on Tuesday.</li>



<li>Maxeon Solar Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/maxn-stock-quote/">MAXN</a>) shares are decreasing more than 15% on <a href="https://seekingalpha.com/article/4682824-maxeon-solar-technologies-preliminary-q4-earnings-dont-buy-this-dip?source=content_type%3Areact%7Csection_asset%3Arelated-analysis%7Csection%3Aright_rail%7Cfirst_level_url%3Aarticle%7Cline%3A1%7Cpos%3Aundefined">preliminary earnings results</a>.</li>



<li>Eco Wave Power Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/wave-stock-quote/">WAVE</a>) stock is dropping over 14% after a <a href="https://investorplace.com/2024/04/why-is-eco-wave-power-wave-stock-up-115-today/">massive rally yesterday</a>.</li>



<li>Guardion Health Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/ghsi-stock-quote/">GHSI</a>) shares are sliding more than 12% on plans for a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318223987&amp;type=PDF&amp;symbol=GHSI&amp;cdn=81af5524a2ccf8e9d81bd1343671bec4&amp;companyName=Guardion+Health+Sciences+Inc.&amp;formType=DEFM14A&amp;formDescription=Definitive+proxy+statement+relating+to+merger+or+acquisition&amp;dateFiled=2024-04-08">special shareholder meeting</a>.</li>



<li>DigiAsia (NASDAQ:<a href="https://investorplace.com/stock-quotes/faas-stock-quote/">FAAS</a>) stock is declining almost 12% after a rally yesterday.</li>



<li>Erayak Power Solution (NASDAQ:<a href="https://investorplace.com/stock-quotes/raya-stock-quote/">RAYA</a>) shares close out our pre-market stock movers down over 11%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-april-9th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

RenovoRx (RNXT) just unveiled an update. On April 11, 2024, the Company successfully completed a notable private placement offering, raising $11.1 ...

RenovoRx Secures $11.1M Through Equity and Warrants Offering

RenovoRx regains compliance with Nasdaq

RenovoRx files to sell 6.96M shares of common stock for holders

Renovorx, Inc. (RNXT) has disclosed a new risk, in the Accounting & Financial Operations category. Renovorx, Inc., a clinical-stage biopharmaceutic...

Biopharmaceutical Challenger Renovorx: Navigating Uncertainty and Financial Risks in Drug Development

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
RenovoRx (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnxt-stock-quote/">RNXT</a>) just reported results for the first quarter of 2024.<ul><li>RenovoRx reported earnings per share of -7 cents. This was above the analyst estimate for EPS of -16 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/rnxt-stock-earnings-renovorx-for-q1-of-2024/">RNXT Stock Earnings: RenovoRx Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RNXT Stock Earnings: RenovoRx Beats EPS for Q1 2024

RenovoRx (RNXT) just unveiled an announcement. At the 2024 annual meeting, the Company successfully elected six directors to a one-year term with o...

RenovoRx Shareholders Unanimously Elect Board Directors

Edward Woo, an analyst from Ascendiant, has initiated a new Buy rating on RenovoRx (RNXT). Edward Woo has given his Buy rating due to a combination...

Buy Rating Endorsed for RenovoRx: Innovative TAMP Platform and Promising RenovoGem Trials

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
RenovoRx (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnxt-stock-quote/">RNXT</a>) just reported results for the second quarter of 2024.<ul><li>RenovoRx reported earnings per share of -10 cents. This met the analyst estimate for EPS of -10 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/rnxt-stock-earnings-renovorx-for-q2-of-2024/">RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024

Maxim Group analyst Jason McCarthy maintained a Buy rating on RenovoRx (RNXT – Research Report) yesterday and set a price target of $4.00. Jason Mc...

Buy Rating Backed by RenovoRx's Clinical Advancements and Sustained Financial Health

ACOR

ADXN

ANGH

BCLI

BPTS

BSGM

DXYZ

FAAS

FCUV

GHSI

MAXN

MDIA

MYMD

RAYA

RNXT

VINC

VVOS

WAVE

Press Releases

Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery

RenovoRx CEO Issues Update Letter to Shareholders

Management

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial

Health Care

RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist®

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

General

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

Comments

RenovoRx

Notizie

Ultime notizie per RenovoRx (NASDAQ:RNXT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO